Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label Extension

Next Previous
X
Search
Trial Profile

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label Extension

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cenobamate (Primary)
  • Indications Complex partial epilepsy; Partial epilepsies; Seizures
  • Focus Registrational; Therapeutic Use
  • Sponsors SK Life Science

    • Most Recent Events

    • 29 Jun 2023 According to an Endo International media release, XCOPRI™ (cenobamate tablets) for adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy received approval from Health Canada.
    • 27 Apr 2023 Results of pooled post hoc analysis assessing effects of adjunctive cenobamate and concomitant antiseizure medications (ASMs) on weight from YKP3089C013 , YKP3089C017 and YKP3089C021 presented at the 75th Annual Meeting of the American Academy of Neurology 2023
    • 06 Dec 2022 Results of pooled, Post-hoc analysis from YKP3089C013 , YKP3089C017 and YKP3089C021 , presented at the 76th Annual Meeting of the American Epilepsy Society

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top